<DOC>
	<DOCNO>NCT01539304</DOCNO>
	<brief_summary>Therapeutic Confirmatory Clinical Trial Evaluate Safety Efficacy `` CITUS Dry Syrup '' Children With Perennial Allergic Rhinitis : Double Blinded , Randomized , Placebo Controlled , Parallel Designed , Multi-centered , Phase III Study .</brief_summary>
	<brief_title>Clinical Trial Evaluate Safety Efficacy `` CITUS Dry Syrup '' Children With Perennial Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>1 . Children age 24 month 15 year . 2 . Patients diagnose perennial allergic rhinitis ImmunoCAP test . 3 . NIS mean total score 1week baseline 4.0 . 1 . Patient accompany seriously abnormal symptom respiratory system , pneumonia , cystic fibrosis , viral influenza , tuberculosis , asthma ( status praesens ) . 2 . Patient cancer , diabetes mellitus , hypertension , CNS disease , metabolic disease need medication . 3 . Patient rhinitis cause allergy . 4 . Acute chronic sinusitis . 5 . Patient medical history allergy seasonal pollen trial . 6 . Patient eye nose surgery within 3 month prior trial . 7 . Patient eye upper airway infection within 1 week prior treatment period . 8 . Beginning immunotherapy dose change within 1 month prior trial . 9 . Patient clinical history sensitivity allergic rhinitis medication . 10 . Patient whose heart function abnormal : include heart failure , abnormal ECG test value clinically significant . 11 . Patient experience participate clinical trial within 2 month prior trial . 12 . Patient take contraindicate medication study within 1 week ( baseline period ) prior treatment period . 13 . For girl first period , result pregnancy test positive .</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>